FindTrial
Sign In

Gefapixant 45 mg BID

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chronic Cough

Phase 3

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
CompletedNCT03449147
Merck Sharp & Dohme LLCChronic Cough
Start: 2018-03-15End: 2020-10-30Updated: 2021-09-02
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension
CompletedNCT04525885
Merck Sharp & Dohme LLCChronic Cough
Start: 2019-05-17End: 2022-09-15Updated: 2024-01-12

Related Papers

S5 Early cough severity changes over the first 4 weeks of treatment with gefapixant in two phase 3 studies
2023-11-01
S3 Gefapixant efficacy and safety in participants with history of refractory or unexplained chronic cough for ≥1 vs <1 year
2023-11-01
Gefapixant efficacy and safety in participants with history of refractory or unexplained chronic cough for ≥1 vs <1 year
2023-09-09
Early cough severity changes over the first 4 weeks of treatment with gefapixant in two phase 3 studies
2023-09-09
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
2022-05-1316 citations
Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
2022-03-01210 citations
P61 Pooled analysis of objective cough frequency in participants with chronic cough treated with gefapixant in two phase 3 clinical trials (COUGH-1 and COUGH-2)
2021-11-012 citations
P59 Baseline characteristics and medical history of patients with refractory or unexplained chronic cough participating in two global phase 3 clinical trials
2021-11-01
Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant
2021-09-051 citations
The Cough Severity Diary in a pooled analysis of two, phase 3 trials of gefapixant in chronic cough
2021-09-05
Validation of a visual analog scale for assessing cough severity in patients with chronic cough
Therapeutic Advances in Respiratory Disease2021-01-0199 citations
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
ERJ Open Research2020-10-0153 citations
Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)
2020-09-0717 citations